Constipation News and Research

Latest Constipation News and Research

Naldemedine shows promise in treating OIC in patients with chronic non-cancer pain.

Shionogi Inc. today announced data from a Phase IIb study that showed 0.2 mg and 0.4 mg of naldemedine demonstrated statistically significant efficacy in treating opioid-induced constipation (OIC) in patients with chronic non-cancer pain.

19 May 2015

Combination therapy provides promising results in patients with advanced non-small cell lung cancer

An early phase study testing an anti-PDL1 agent in combination with standard chemotherapy in the treatment of advanced non-small cell lung cancer has provided promising early results, prompting multiple phase III studies in lung cancer. The findings are being presented at the annual meeting of the American Society of Clinical Oncology.

15 May 2015

Simple blood tests diagnose irritable bowel syndrome quickly and accurately

Millions of people afflicted by irritable bowel syndrome can now be diagnosed quickly and accurately with two simple blood tests developed by a Cedars-Sinai gastroenterologist.

14 May 2015

Research finding could lead to better treatments for inflammatory bowel disease

Inflammatory bowel disease (IBD) afflicts 1.6 million people in the United States, causing abdominal pain, diarrhea, constipation, rectal bleeding and other potentially debilitating symptoms.

14 May 2015

Scripps Florida scientists win $2.4 million to expand development of new pain therapies

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded $2.4 million from the National Institute on Drug Abuse of The National Institutes of Health to expand development of new pain medications with fewer side effects than those currently available...

8 May 2015

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015.

8 May 2015

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Australian biopharmaceutical company Specialised Therapeutics Australia and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration has approved AKYNZEO for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy.

8 May 2015

Enhanced recovery program for patients undergoing colorectal operations speeds patients' recovery

Patients undergoing colorectal operations who participated in an enhanced recovery program left the hospital sooner and had significantly lower hospital costs than patients who had the traditional approach to their care, according to a new study, which also found further postoperative improvements after adding an infection prevention protocol.

8 May 2015

Preclinical data from Synthetic Biologics' SYN-005 for Pertussis treatment presented at ECCMID 2015

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced that preclinical data from its novel SYN-005 program for the treatment of Pertussis were presented in two posters at ECCMID 2015 (European Congress of Clinical Microbiology and Infectious Diseases), on April 25, 2015, in Copenhagen, Denmark.

27 Apr 2015

Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older.

25 Apr 2015

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ.

13 Apr 2015

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Rhythm, a biopharmaceutical company, and Actavis plc, a leading global pharmaceutical company, announced today the initiation of a Phase 2b clinical trial assessing the efficacy and safety of relamorelin (RM-131), Rhythm's ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes.

8 Apr 2015

New study analyses physical, psychological consequences of bariatric surgery

Bariatric surgery, or reduction of gastric capacity, is one of the longer lasting options to achieve considerable weight loss in obese people. A Spanish researcher has participated in a study that confirms that the effects of this relatively complex medical surgery are not only physical, but also psychological.

8 Apr 2015

Combining nortriptyline and morphine successfully relieves chronic neuropathic pain

The combination of two well-known drugs will have unprecedented effects on pain management, says new research from Queen's.

8 Apr 2015

Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

Astellas Pharma Inc. and Medivation, Inc. today announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide in a study population of men with non-metastatic or metastatic castration-resistant prostate cancer.

2 Apr 2015

EnteroMedics, American HealthCare Lending partner to support patient access to vBloc Therapy

EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the Company has entered into a partnership with American HealthCare Lending to provide funding for patient access to vBloc Therapy, delivered via the Maestro Rechargeable System, for the treatment of obesity.

1 Apr 2015

Shire announces availability of Natpara (parathyroid hormone) for injection in U.S.

Shire plc today announced that Natpara (parathyroid hormone) for injection is now available in the United States. The U.S. Food and Drug Administration approved Natpara as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism on January 23, 2015.

1 Apr 2015

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

Nektar Therapeutics reported that partner AstraZeneca announced today that MOVANTIK (naloxegol) has launched in the United States. On September 16, 2014, the US Food and Drug Administration (FDA) approved MOVANTIK as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain.

31 Mar 2015

Synthetic Biologics begins SYN-004 Phase 2a clinical trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced the initiation of a Phase 2a clinical trial to evaluate the gastrointestinal (GI) antibiotic-degrading effects and the safety of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent C. difficile infection (CDI).

30 Mar 2015

Naldemedine meets primary and secondary endpoints in phase III study for OIC treatment

Naldemedine, an investigational peripherally acting mu-opioid receptor antagonist (PAMORA) under development by Shionogi & Co., Ltd., met its primary and secondary endpoints in a phase III study (COMPOSE I) for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain receiving opioid therapy.

30 Mar 2015

Constipation News and Research

Latest Constipation News and Research

Naldemedine shows promise in treating OIC in patients with chronic non-cancer pain.

Combination therapy provides promising results in patients with advanced non-small cell lung cancer

Simple blood tests diagnose irritable bowel syndrome quickly and accurately

Research finding could lead to better treatments for inflammatory bowel disease

Scripps Florida scientists win $2.4 million to expand development of new pain therapies

Orexigen Therapeutics provides update on business and financial results for Q1 2015

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Enhanced recovery program for patients undergoing colorectal operations speeds patients' recovery

Preclinical data from Synthetic Biologics' SYN-005 for Pertussis treatment presented at ECCMID 2015

Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

New study analyses physical, psychological consequences of bariatric surgery

Combining nortriptyline and morphine successfully relieves chronic neuropathic pain

Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

EnteroMedics, American HealthCare Lending partner to support patient access to vBloc Therapy

Shire announces availability of Natpara (parathyroid hormone) for injection in U.S.

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

Synthetic Biologics begins SYN-004 Phase 2a clinical trial to prevent C. difficile infection

Naldemedine meets primary and secondary endpoints in phase III study for OIC treatment

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Constipation News and Research

Latest Constipation News and Research

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in